Vistagen Therapeutics Inc. Common Stock (VTGN)
Stock · NASDAQ · Health Care
$0.2as of 10/16/2026
Price chart
Active signals
VTGN Signal Track Record
How signals performed across all stocks →What VTGN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 46 | -10.5% | 37% | September 22, 2026 |
| Bollinger Band Breakout | 24 | -13.2% | 17% | September 23, 2026 |
| Bollinger Band Breakdown | 24 | +0.9% | 50% | June 30, 2026 |
| Any 20-session window (baseline) | -2.9% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About VTGN
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic inve…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 41
- Website
- www.vistagen.com/
Fundamentals
- 1-day range
- $0.1977$0.2187
- Market cap
- $12.59M
- P/E (trailing)
- —
- P/E (forward)
- -0.13
- EPS (trailing)
- $-1.68
- Dividend yield
- —
- Beta
- 0.48
- Avg. volume
- 12.34M
How Vistagen Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2026 annual results
Source: 10-K filed Jun 15, 2026 · via SEC EDGAR / Finnhub
Forecasts
2 analyst ratings
Vistagen Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- VTGNVistagen Therapeutics Inc. Common Stock$0.2▼ 4.76%Market cap $12.59MP/E —$0.198$5.14
- PHIOPhio Pharmaceuticals Corp. Common Stock$0.871▼ 5.94%Market cap $12.31MP/E —$0.8127$4.19
- CMMBChemomab Therapeutics Ltd. American Depositary Share$1.26▼ 1.94%Market cap $12.95MP/E —$1.05$3.5
- BLRXBioLineRx Ltd. American Depositary Shares$2.01▼ 1.95%Market cap $12.14MP/E Infinity$1.1$2.3
- PBMPsyence Biomedical Ltd. Common Shares$4.22▼ 2.31%Market cap $13.31MP/E —$1.92$143.5
- GTBPGT Biopharma Inc. Common Stock$7.03▼ 4.48%Market cap $13.35MP/E —$4.91$34.25
- AEONAEON Biopharma Inc. Class A Common Stock$0.232▼ 4.53%Market cap $13.80MP/E —$0.1772$1.45
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VTGN Vistagen Therapeutics Inc. Common Stock | $12.59M | — | $0.2 | ▼ 4.76% | $0.198$5.14 |
| PHIO Phio Pharmaceuticals Corp. Common Stock | $12.31M | — | $0.871 | ▼ 5.94% | $0.8127$4.19 |
| CMMB Chemomab Therapeutics Ltd. American Depositary Share | $12.95M | — | $1.26 | ▼ 1.94% | $1.05$3.5 |
| BLRX BioLineRx Ltd. American Depositary Shares | $12.14M | Infinity | $2.01 | ▼ 1.95% | $1.1$2.3 |
| PBM Psyence Biomedical Ltd. Common Shares | $13.31M | — | $4.22 | ▼ 2.31% | $1.92$143.5 |
| GTBP GT Biopharma Inc. Common Stock | $13.35M | — | $7.03 | ▼ 4.48% | $4.91$34.25 |
| AEON AEON Biopharma Inc. Class A Common Stock | $13.80M | — | $0.232 | ▼ 4.53% | $0.1772$1.45 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Vasomotor Symptoms Market Poised for Growth Through 2036, Driven by Rising Adoption of Hormonal and Non-Hormonal Therapies | DelveInsightYahoo · 9/30/2026
- 2 Falling Stocks Call Traders Are Targeting TodayYahoo · 9/25/2026
- SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)Yahoo · 9/24/2026
- Vistagen Presents Fasedienol Subgroup Data in Severe Social Anxiety DisorderYahoo · 9/24/2026
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga · 9/24/2026
- Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety DisorderYahoo · 9/24/2026
- Vistagen Presents Exploratory Data At Psych Congress 2026 Highlighting Potential Efficacy Signal For Phase 3 Fasedienol Nasal Spray In Patients With Very Severe Social Anxiety DisorderBenzinga · 9/24/2026
- Let's take a look at the stocks that are in motion in today's session.ChartMill · 9/23/2026
Insider Activity
Insider Actions →- Williamson Douglas J · July 29, 2026 · Grant40.8K
- Adler Reid G. · June 30, 2026 · Grant36.8K @ $0.1921
- Tressler Nick B. · June 30, 2026 · Grant11.7K @ $0.1921
- Singh Shawn · June 30, 2026 · Grant36.8K @ $0.1921
- Angelov Angel S · May 18, 2026 · Grant150.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 15.06M
- Total value held
- $7.93M
- Institutional holders
- 54
- Unknown3.06M
- Unknown2.68M
- Unknown1.57M
- Unknown751.1K
- Unknown644.4K
- Unknown616.7K
- Unknown589.7K
- Unknown519.1K
- Unknown469.6K
- Unknown453.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
VTGN linked to growing vasomotor symptoms market amid recent price dip
The vasomotor symptoms market is projected to expand through 2036 as adoption of hormonal and non‑hormonal therapies rises, a trend that aligns with VTGN’s focus on treatments for menopausal symptoms. At the same time, VTGN appeared on a recent list of falling stocks that traders are watching, indicating recent price weakness. These factors together provide context for the stock’s current market environment.
VTGN linked to growing vasomotor symptoms market amid recent price dip. The vasomotor symptoms market is projected to expand through 2036 as adoption of hormonal and non‑hormonal therapies rises, a trend that aligns with VTGN’s focus on treatments for menopausal symptoms. At the same time, VTGN appeared on a recent list of falling stocks that traders are watching, indicating recent price weakness. These factors together provide context for the stock’s current market environment.